(TheNewswire)
VANCOUVER, BC / TheNewswire / May 27, 2022 / AREV LIFE SCIENCES GLOBAL CORP. (CSE:AREV)(OTC:AREVF) (“AREV” or the “Company”) is pleased to announcethe issuance of the retention warrant offering as announced April 8,2022.
AREV is pleased to announce aretention warrant offering to its senior management of Mike Withrow,CEO, and Kevin Phelps, COO. Each of the retention warrants are beingsold to the purchase price of $0.05 per retention share purchasewarrant and exercisable at $0.23 per common share during a term of 4years from the date of closing of the retention warrant offering. Theexercise of such warrant shall be subject to the occurrence of thefollowing events:
ITEM | PERCENTAGE/# of Warrants | Exercisability Provision in regard of the Warrant Holder |
i. | 20% | Signing of Executive Consulting Agreement |
ii. | 15% | Conclusion of one year of Employment |
iii. | 15% | Conclusion of two years of Employment |
iv. | 15% | Conclusion of three years of Employment |
vi. | 35% | Completion of any two of pre-established strategic initiatives. “Completion” is to be defined as a closed deal in which allparties have executed final agreements and the Company has takenownership of any assets or funds. All agreements must be approved bythe CSE and agree with all governing regulations. Any agreement deemedto be outside of the regulations will be deemed to have not completed. |
Insiders of the Company participationin the foregoing offering constitutes a "related partytransaction" as defined under Multilateral Instrument 61-101Protection of Minority Security Holders in Special Transactions (“MI61-101”). Such participation is exempt from the formal valuation andminority shareholder approval requirements of MI 61-101 as neither thefair market value of the securities acquired by the insiders, nor theconsideration for the securities paid by such insiders, exceed 25% ofthe Company's market capitalization.
For further information, contact Mike Withrow,arevlifesciences@gmail.com 778-929-6536. For more information visitwww.arevlifesciences.com.
On behalf of the Board,
Mike Withrow
CEO &Director
About AREV Life Sciences GlobalCorp.
AREV is an early-stage life science discoveryenterprise dedicated to delivering solutions to public health throughdiscovery, collaborations in the life science industry, and pathogenremediation. AREV is invested in commercial innovations inphytomedicinal discoveries of small molecule antivirals and forrelated neglected chronic co-morbidities and innovations humannutrition including the late-stage development of a Ready-to-UseTherapeutic Food (RUTF) for Severe Acute Malnutrition (SAM) and anEnteral Formula targeting the long-term effects of chronic infection.AREV is dedicated to designing and delivering innovation in rationaldrug design, driven by presenting global epidemiologicalcharacteristics of multiple challenges to international human andanimal health. AREV is a member of both BIOTECanada and TheBiotechnology Innovation Organization (BIO).
NEITHER THE CANADIAN SECURITIES EXCHANGENOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPTRESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THISRELEASE.
FORWARD LOOKINGINFORMATION
Neither the Canadian Securities Exchangenor its Regulation Services Provider (as that term is defined inpolicies of the CSE) accepts responsibility for the adequacy oraccuracy of this release. This news release may includeforward-looking statements that are subject to risks anduncertainties. All statements within, other than statements ofhistorical fact, are to be considered forward looking. Although theCompany believes the expectations expressed in such forward lookingstatements are based on reasonable assumptions, such statements arenot guarantees of future performance and actual results ordevelopments may differ materially from those in forward-lookingstatements. Factors that could cause actual results to differmaterially from those in forward-looking statements include marketprices, exploitation and exploration successes, and continuedavailability of capital and financing, and general economic, market orbusiness conditions. There can be no assurances that such statementswill prove accurate and, therefore, readers are advised to rely ontheir own evaluation of such uncertainties. We do not assume anyobligation to update any forward-looking statements except as required
under the applicable laws. This pressrelease contains forward-looking statements. The use of any of thewords "anticipate", "continue","estimate", "expect", "may","will", "project", "should","believe" and similar expressions are intended to identifyforward-looking statements. Although the Company believes that theexpectations and assumptions on which the forward-looking statementsare based are reasonable, undue reliance should not be placed on theforward-looking statements because the Company can give no assurancethat they will prove to be correct. Since forward-looking statements
address future events and conditions, bytheir very nature they involve inherent risks and uncertainties. Thesestatements speak only as of the date of this press release. Actualresults could differ materially from those currently anticipated dueto a number of factors and risks various risk factors discussed in theCompany’ sManagement ’s Discussionand Analysis under the Company’s profile on www.sedar.com.
Copyright (c) 2022 TheNewswire - All rights reserved.